Suppr超能文献

体外扩增自然杀伤细胞富集淋巴细胞(MYJ1633)对肝癌的细胞毒作用。

Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.

机构信息

Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do, 25601, Republic of Korea.

IMMUNISBIO Co., Ltd, International St. Mary's Hospital, Incheon Metropolitan City, 22711, Republic of Korea.

出版信息

BMC Cancer. 2019 Aug 19;19(1):817. doi: 10.1186/s12885-019-6034-1.

Abstract

BACKGROUND

Adoptive transfer of immune cells such as T cells and natural killer (NK) cells has emerged as a targeted method of controlling the immune system against cancer. Despite their significant therapeutic potential, efficient methods to generate adequate numbers of NK cells are lacking and ex vivo-expansion and activation of NK cells is currently under intensive investigation. The primary purpose of this study was to develop an effective method for expansion and activation of the effector cells with high proportion of NK cells and increasing cytotoxicity against liver cancer in a short time period.

METHODS

Expanded NK cell-enriched lymphocytes (NKL) designated as "MYJ1633" were prepared by using autologous human plasma, cytokines (IL-2, IL-12 and IL-18) and agonistic antibodies (CD16, CD56 and NKp46) without an NK cell-sorting step. The characteristics of NKL were compared to those of freshly isolated PBMCs. In addition, the cytotoxic effect of the NKL on liver cancer cell was examined in vitro and in vivo.

RESULTS

The total cell number after ex vivo-expansion increased about 140-fold compared to that of freshly isolated PBMC within 2 weeks. Approximately 78% of the expanded and activated NKL using the house-developed protocol was NK cell and NKT cells even without a NK cell-sorting step. In addition, the expanded and activated NKL demonstrated potent cytotoxicity against liver cancer in vitro and in vivo.

CONCLUSION

The house-developed method can be a new and effective strategy to prepare clinically applicable NKL for autologous NK cell-based anti-tumor immunotherapy.

摘要

背景

过继转移免疫细胞,如 T 细胞和自然杀伤(NK)细胞,已成为一种靶向控制免疫系统对抗癌症的方法。尽管它们具有显著的治疗潜力,但缺乏产生足够数量 NK 细胞的有效方法,目前正在深入研究 NK 细胞的体外扩增和激活。本研究的主要目的是开发一种有效的方法,在短时间内扩增和激活具有高 NK 细胞比例和增加对肝癌细胞的细胞毒性的效应细胞。

方法

使用自体人血浆、细胞因子(IL-2、IL-12 和 IL-18)和激动性抗体(CD16、CD56 和 NKp46),无需 NK 细胞分选步骤,制备扩增的 NK 细胞丰富的淋巴细胞(NKL),命名为“MYJ1633”。比较了 NKL 的特征与新鲜分离的 PBMC 的特征。此外,还在体外和体内检查了 NKL 对肝癌细胞的细胞毒性作用。

结果

与新鲜分离的 PBMC 相比,在 2 周内,体外扩增后的总细胞数增加了约 140 倍。即使没有 NK 细胞分选步骤,使用我们自主开发的方案扩增和激活的 NKL 中约 78%是 NK 细胞和 NKT 细胞。此外,扩增和激活的 NKL 在体外和体内均表现出对肝癌的强大细胞毒性。

结论

该自主研发的方法可以成为一种新的有效的策略,用于制备用于自体 NK 细胞为基础的抗肿瘤免疫治疗的临床适用的 NKL。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b65/6700835/e1d3d91484c6/12885_2019_6034_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验